Abeona Therapeutics (NASDAQ:ABEO) SVP Sells $72,370.74 in Stock

by · The Markets Daily

Abeona Therapeutics Inc. (NASDAQ:ABEO – Get Free Report) SVP Brendan O’malley sold 13,578 shares of Abeona Therapeutics stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $5.33, for a total transaction of $72,370.74. Following the sale, the senior vice president owned 451,134 shares in the company, valued at approximately $2,404,544.22. This trade represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Abeona Therapeutics Price Performance

NASDAQ ABEO traded up $0.05 on Thursday, reaching $5.36. The company’s stock had a trading volume of 1,363,791 shares, compared to its average volume of 982,818. Abeona Therapeutics Inc. has a 52 week low of $3.93 and a 52 week high of $7.54. The company has a current ratio of 9.74, a quick ratio of 9.53 and a debt-to-equity ratio of 0.06. The firm has a market cap of $290.46 million, a PE ratio of 4.36 and a beta of 1.12. The business has a 50-day moving average price of $5.07 and a 200 day moving average price of $5.64.

Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last announced its quarterly earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.17. Sell-side analysts expect that Abeona Therapeutics Inc. will post -1.16 EPS for the current year.

Institutional Investors Weigh In On Abeona Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. raised its position in Abeona Therapeutics by 49.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,450 shares of the biopharmaceutical company’s stock valued at $954,000 after purchasing an additional 66,422 shares during the last quarter. Riverwater Partners LLC acquired a new stake in shares of Abeona Therapeutics in the second quarter valued at $62,000. Y Intercept Hong Kong Ltd bought a new position in shares of Abeona Therapeutics in the second quarter valued at about $581,000. Los Angeles Capital Management LLC acquired a new position in Abeona Therapeutics during the 2nd quarter worth about $1,523,000. Finally, Simplify Asset Management Inc. lifted its position in Abeona Therapeutics by 36.7% during the 2nd quarter. Simplify Asset Management Inc. now owns 558,584 shares of the biopharmaceutical company’s stock worth $3,173,000 after buying an additional 150,000 shares in the last quarter. 80.56% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ABEO has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Abeona Therapeutics in a research note on Monday, October 13th. Weiss Ratings cut Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 24th. Finally, Wall Street Zen lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Abeona Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

View Our Latest Analysis on Abeona Therapeutics

About Abeona Therapeutics

(Get Free Report)

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.

Read More